4.61
Precedente Chiudi:
$4.81
Aprire:
$4.8
Volume 24 ore:
357.55K
Relative Volume:
0.80
Capitalizzazione di mercato:
$279.07M
Reddito:
-
Utile/perdita netta:
$-69.31M
Rapporto P/E:
-3.6299
EPS:
-1.27
Flusso di cassa netto:
$-62.80M
1 W Prestazione:
-6.11%
1M Prestazione:
-2.33%
6M Prestazione:
+5.98%
1 anno Prestazione:
+271.77%
Rezolute Inc Stock (RZLT) Company Profile
Nome
Rezolute Inc
Settore
Industria
Telefono
650-206-4507
Indirizzo
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Confronta RZLT con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
RZLT
Rezolute Inc
|
4.61 | 279.07M | 0 | -69.31M | -62.80M | -1.27 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
459.00 | 117.92B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
673.60 | 73.64B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
639.41 | 38.85B | 1.86B | -40.29M | -1.28B | -0.85 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
256.45 | 33.20B | 2.09B | -332.26M | 16.06M | -2.62 |
![]()
BNTX
Biontech Se Adr
|
119.83 | 28.73B | 3.30B | -501.07M | 1.03B | -2.1146 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-05 | Iniziato | Wedbush | Outperform |
2024-08-27 | Iniziato | Guggenheim | Buy |
2024-07-17 | Iniziato | BTIG Research | Buy |
2024-06-04 | Iniziato | Craig Hallum | Buy |
2024-04-09 | Iniziato | Maxim Group | Buy |
2022-08-02 | Ripresa | Canaccord Genuity | Buy |
2022-06-15 | Iniziato | Cantor Fitzgerald | Overweight |
2021-09-08 | Iniziato | ROTH Capital | Buy |
2021-05-27 | Iniziato | Oppenheimer | Outperform |
2021-05-25 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Rezolute Inc Borsa (RZLT) Ultime notizie
Rezolute’s Strategic Advances in Rare Disease Therapies - TipRanks
Rezolute (NASDAQ:RZLT) Given New $9.00 Price Target at JMP Securities - MarketBeat
Rezolute's (RZLT) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
JMP Securities lifts Rezolute stock target to $9, maintains rating - MSN
JMP Securities lifts Rezolute stock target to $9, maintains rating By Investing.com - Investing.com South Africa
Rezolute (NASDAQ:RZLT) Issues Quarterly Earnings Results - MarketBeat
Rezolute Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Rezolute Inc. (RZLT) reports earnings - Quartz
Rezolute, Inc. SEC 10-Q Report - TradingView
Rezolute's Hyperinsulinism Drug Hits Major FDA Milestone as Q2 Shows $105M War Chest - StockTitan
Analysts Set Rezolute, Inc. (NASDAQ:RZLT) PT at $24.13 - Defense World
H.C. Wainwright reiterates Buy on Rezolute shares, $14 target - MSN
Rezolute (NASDAQ:RZLT) Receives Buy Rating from Guggenheim - Defense World
Rezolute (NASDAQ:RZLT) Receives "Buy" Rating from Guggenheim - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Rezolute (NASDAQ:RZLT) Raised to Strong-Buy at Craig Hallum - MarketBeat
Rezolute (NASDAQ:RZLT) Given Buy Rating at HC Wainwright - MarketBeat
Rezolute’s (RZLT) Buy Rating Reiterated at HC Wainwright - Defense World
Rezolute Inc (RZLT) Shares Decline Despite Market Challenges - The News Heater
Analytical Overview: Rezolute Inc (RZLT)’s Ratios Tell a Financial Story - The Dwinnex
Rezolute (RZLT) to Announce Earnings on Tuesday - MarketBeat
Rezolute (NASDAQ:RZLT) Upgraded at Craig Hallum - Defense World
RZLT Shares Rise 30.8% in 6 Months: What's Driving the Rally? - MSN
What is the investor’s view on Rezolute Inc (RZLT)? - US Post News
Rezolute's ersodetug advances in pediatric study - MSN
The Attractiveness of Investing In Rezolute Inc (RZLT) is Growing - Knox Daily
H.C. Wainwright reiterates Buy on Rezolute shares, $14 target By Investing.com - Investing.com South Africa
JPMorgan Chase & Co. Purchases New Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Advances SunRIZE Study for Hypoglycemia Treatment - TipRanks
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism - Marketscreener.com
Rezolute, Inc. Reports Positive DMC Review of sunRIZE Study for Ersodetug in Infants with Hyperinsulinism - Nasdaq
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to - EIN News
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference -February 03, 2025 at 09:06 am EST - Marketscreener.com
(RZLT) Trading Report - Stock Traders Daily
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference - The Manila Times
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference -January 31, 2025 at 08:01 am EST - Marketscreener.com
Rare Disease Pioneer Rezolute Takes Center Stage at Elite Guggenheim Biotech Conference - StockTitan
Rezolute receives breakthrough therapy designation for treatment of hypoglycemia - MSN
Cantor Fitzgerald Predicts Rezolute FY2025 Earnings - MarketBeat
Rezolute, Inc. (NASDAQ:RZLT) Receives $24.13 Average Target Price from Analysts - Defense World
Brokerages Set Rezolute, Inc. (NASDAQ:RZLT) Price Target at $24.13 - MarketBeat
Rezolute shares Phase 2 clinical study update By Investing.com - Investing.com South Africa
Rezolute shares Phase 2 clinical study update - Investing.com
Rezolute Highlights Promising Phase 2 Ersodetug Results - TipRanks
(RZLT) On The My Stocks Page - Stock Traders Daily
Top 5 Small-cap Biotech Stocks (Updated January 2025) - Investing News Network
Rezolute, Inc. (NASDAQ:RZLT) Shares Acquired by Geode Capital Management LLC - MarketBeat
Rezolute Gains FDA Breakthrough Designation for Ersodetug - TipRanks
Here's Why 'Trend' Investors Would Love Betting on Rezolute (RZLT) - Yahoo Finance
FDA Grants Breakthrough Therapy Status to Rezolute's Ersodetug for Congenital Hyperinsulinism - StockTitan
Rezolute Inc Azioni (RZLT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):